Lakefront Biotherapeutics NV
LKFTNasdaqCIK 1421876Healthcare
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: not reported
Last eight quarters
Full statements| Line item | Unit | Shape over the periods |
|---|---|---|
| Revenue | $ | |
| Gross margin | % | |
| Operating margin | % | |
| Net margin | % | |
| Diluted EPS | $ per share | |
| Free cash flow | $ |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-12-31 | FY20222022-12-31 | FY20232023-12-31 | FY20242024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $m | 234Revenue, FY2021, twelve months to 2021-12-31EUR 234.4m. XBRL concept ifrs-full:Revenue. 20-F filed 2024-03-28, accession 0001558370-24-004242.Report this figure | 241Revenue, FY2022, twelve months to 2022-12-31EUR 241.2m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-03-27, accession 0001558370-25-003806.Report this figure | 240Revenue, FY2023, twelve months to 2023-12-31EUR 239.7m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | 276Revenue, FY2024, twelve months to 2024-12-31EUR 275.6m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | 1,112Revenue, FY2025, twelve months to 2025-12-31EUR 1.11bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | (73.2%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −EUR 171.6m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2024-03-28, accession 0001558370-24-004242.Revenue: EUR 234.4m. XBRL concept ifrs-full:Revenue. 20-F filed 2024-03-28, accession 0001558370-24-004242.Report this figure | (54.3%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −EUR 131.1m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2025-03-27, accession 0001558370-25-003806.Revenue: EUR 241.2m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-03-27, accession 0001558370-25-003806.Report this figure | (36.8%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −EUR 88.3m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-03-26, accession 0001104659-26-035163.Revenue: EUR 239.7m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | (68.3%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −EUR 188.3m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-03-26, accession 0001104659-26-035163.Revenue: EUR 275.6m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | 26.5%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: EUR 295.0m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-03-26, accession 0001104659-26-035163.Revenue: EUR 1.11bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | |
| Net margin | % | (44.0%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −EUR 103.2m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2024-03-28, accession 0001558370-24-004242.Revenue: EUR 234.4m. XBRL concept ifrs-full:Revenue. 20-F filed 2024-03-28, accession 0001558370-24-004242.Report this figure | (90.4%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −EUR 218.0m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2025-03-27, accession 0001558370-25-003806.Revenue: EUR 241.2m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-03-27, accession 0001558370-25-003806.Report this figure | 88.3%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: EUR 211.7m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-03-26, accession 0001104659-26-035163.Revenue: EUR 239.7m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | 26.9%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: EUR 74.1m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-03-26, accession 0001104659-26-035163.Revenue: EUR 275.6m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | 28.9%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: EUR 320.9m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-03-26, accession 0001104659-26-035163.Revenue: EUR 1.11bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | |
| Diluted EPS | $ per share | (1.58)Diluted EPS, FY2021, twelve months to 2021-12-31−EUR 1.58 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2024-03-28, accession 0001558370-24-004242.Report this figure | (3.32)Diluted EPS, FY2022, twelve months to 2022-12-31−EUR 3.32 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-03-27, accession 0001558370-25-003806.Report this figure | 3.21Diluted EPS, FY2023, twelve months to 2023-12-31EUR 3.21 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | 1.12Diluted EPS, FY2024, twelve months to 2024-12-31EUR 1.12 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | 4.87Diluted EPS, FY2025, twelve months to 2025-12-31EUR 4.87 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | |
| Free cash flow | $m | (558)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −EUR 503.8m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2024-03-28, accession 0001558370-24-004242.Capital expenditure: EUR 54.2m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2024-03-28, accession 0001558370-24-004242.Report this figure | (528)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −EUR 500.5m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-03-27, accession 0001558370-25-003806.Capital expenditure: EUR 27.4m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-03-27, accession 0001558370-25-003806.Report this figure | (425)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −EUR 406.0m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-03-26, accession 0001104659-26-035163.Capital expenditure: EUR 18.7m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | (337)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −EUR 320.0m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-03-26, accession 0001104659-26-035163.Capital expenditure: EUR 16.7m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure | (271)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −EUR 257.5m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-03-26, accession 0001104659-26-035163.Capital expenditure: EUR 13.7m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-03-26, accession 0001104659-26-035163.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 2026-06-30 | $500.2m | 16,707,477 | Unchanged | |
| TANG CAPITAL MANAGEMENT LLC | 2026-06-30 | $113.5m | 3,785,991 | Unchanged | |
| Madison Avenue Partners, LP | 2026-06-30 | $103.4m | 3,447,807 | Added+982,628 | |
| Prosight Management, LP | 2026-06-30 | $61.3m | 2,043,344 | Added+493,344 | |
| EcoR1 Capital, LLC | 2026-06-30 | $50.0m | 1,667,119 | Unchanged | |
| AMERIPRISE FINANCIAL INC | 2026-06-30 | $38.1m | 1,272,249 | Reduced−152,425 | |
| DME Capital Management, LP | 2026-06-30 | $14.5m | 482,746 | Unchanged | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2026-06-30 | $13.5m | 449,100 | Put | Reduced−200 |
| RENAISSANCE TECHNOLOGIES LLC | 2026-06-30 | $12.2m | 407,800 | Added+92,400 | |
| BlackRock, Inc. | 2026-06-30 | $10.1m | 338,152 | Added+26,046 |
Recent filings
All 528 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2020:36 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-20 | 0001171843-26-006723 |
| 2026-10-1522:26 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-14 | 0001171843-26-006634 |
| 2026-10-1320:36 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-13 | 0001171843-26-006602 |
| 2026-10-0921:26 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-08 | 0001171843-26-006564 |
| 2026-10-0620:55 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-06 | 0001171843-26-006469 |
| 2026-09-2920:39 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-29 | 0001171843-26-006292 |
| 2026-09-2323:06 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-22 | 0001171843-26-006176 |
| 2026-09-1520:27 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-15 | 0001171843-26-006055 |
| 2026-09-0821:24 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-08 | 0001171843-26-005923 |
| 2026-09-0820:44 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-08 | 0001171843-26-005922 |
Latest annual report
Form 20-F for the fiscal year ended Dec 31, 2025Filed Mar 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1421876
- Tickers
- LKFT, GLPGF
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- not reported
- Incorporated in
- C9
- Filer category
- Large accelerated filer
- Former names
- GALAPAGOS NV (to 2026-05-06)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. Listed shows no prices and gives no investment advice.